AzTrials
AzTrials

Angelman SyndromeNCT06115109

Angelman Natural History Study - FAST Spain

An observational study of Angelman Syndrome, run by Puerta de Hierro University Hospital at 2 sites in Spain.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The goal of this study is to conduct a prospective, longitudinal study to observe the natural clinical progression and disease outcome of AS patients receiving no disease-modified intervention, with the purpose of obtaining data that will be useful for future clinical trials. Read more about this study

Who is it for?
Ages 3 months to 99 years
Conditions the study is for
Angelman Syndrome
What is being tested?
Non intervention, Observational study
How many people
40 participants
Where
2 sitesSpain
Study dates
1 Dec 2023to 1 Jul 2025
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 3 months to 99 years
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: All individuals with a molecular diagnosis of Angelman syndrome

Who may be able to join

  • Male or female between 3 months and 99 years of age.
  • Clinical diagnosis of Angelman Syndrome and molecular confirmation of the diagnosis.
  • The participant has an acceptable guardian capable of giving consent on behalf of the participant,
  • Willingness and ability of their guardians to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Who cannot join

  • Patients with any comorbidity that, in the clinical judgment of the principal investigator, may affect the results of the study. Any confirmed chronic or acute condition or illness affecting any system(s) that could interfere with study results and/or compliance with study procedures is included.
  • Patients who are participating in parallel studies with investigational drugs.
  • Unwillingness or inability of their guardians to follow the procedures outlined in the protocol.

Trial locations and contacts

2 sites in 1 country.

BELEN RUIZ ANTORAN, MD, Ph contact

+34911917479

bruizantoran@gmail.com

Spain2 sites, 2 recruiting
  • Hospital Parc Tauli. Servicio de Genética molecular

    Barcelona, 08208

    Neus Baena Diez, (+34) 93 6933200, NBaena@tauli.cat

    Ariadna Ramírez Mallafré, MD, Ph

    Recruiting
  • Servicio de Farmacología Clínica. Hospital Universitario Puerta de Hierro Majadahonda

    Madrid, 28049

    Belen Ruiz Antorán, MD, Ph, (+34) 91 1917479, bruizantoran@gmail.com

    M Rosario Cazorla Calleja, MD

    Recruiting

Other trials in Spain

About this study

Official title: Observational Study, Prospective Multicentric, From the Natural History of Patients With Angelman Syndrome in Spain

The goal of this study is to conduct a prospective, longitudinal study to observe the natural clinical progression and disease outcome of AS patients receiving no disease-modified intervention, with the purpose of obtaining data that will be useful for future clinical trials.

Read the detailed description

The overall goal is to increase our understanding of the long-term natural history of Angelman syndrome and to identify and validate objective and sensitive outcome measures, which could serve as endpoints for outcome measures that can be used in clinical trials.

Being tested
Non intervention, Observational study
Medical subject headings
Angelman Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Non intervention, Observational studyOther

    Non intervention, Observational study

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Clinical Global Impression Scale for AS (CGI-AS)

    Medical and neurological evaluation:

    -Clinical Global Impression Scale for AS (CGI-AS). The scale consists of several categories, from "not assessed" to "extremely severe." Professionals assess various aspects of behavior, communication, and the individual's overall functioning to assign a score on the CGI-AS scale. A higher score indicates a greater severity of symptoms, while a lower score indicates less severity.

    Measured: 2 years

  2. Hammersmith Neonatal Neurological Examination (HINE) (for 0-2 years)

    Medical and neurological evaluation:

    Hammersmith Neonatal Neurological Examination (HINE). 26 items that assess neurological function (cranial nerve function, posture, movements, tone, reflexes, and reactions). For neurological function, each item is individually scored on a scale of 0 to 3 based on descriptions and illustrative diagrams, so the total score can range from a minimum of 0 to a maximum of 78.

    Measured: 2 years

Secondary outcomes (12)
  1. Movement through actimetry

    Continuous monitoring of movement through actimetry. Actigraphs will we placed on the non-dominant wrist or ankle of each participant. The motionlogger measures long-term gross motor activity and integrates degree and intensity of motion, and contains an accelerometer capable of sensing any motion with minimal resultant force of .01g. Actigraphy measurements will we recorded by the motionlogger every second using the proportional integrating measurement (PIM) mode of operation. In PIM mode, a numeric scale of movement activity is provided based on the absolute value of the area under the sensor curve. The PIM data can range from zero, corresponding to no movement when the limb is at rest, to a maximum value of 32,000, corresponding to the most vigorous and extreme movement of the limb.

    Measured: 2 years

  2. Motor function scales

    Motor function scales:

    • Functional Mobility Scale (FMS). The FMS classifies the functional mobility of children 4-18 years of age taking into account the assistive devices a child might use.

    3 items (distances), each of which is rated from 1-6 depending on assistance required, or "C" for crawling or "N" if distance is not completed Maximum score is a 6 for each of the distances (5m, 50m, and 500m)

    Measured: 2 years

  3. Global development: Bayley Scale-3 (BSID-3)

    -Bayley Scale-3 (BSID-3), at the time that version 4 of the Bayley scale (BSID-4) is validated in Spanish, it will be used in the context of the registry.

    Bayley Scales of Infant Development III, cognitive scale; raw scores used to reflect change over time and absolute growth (rather than standard scores) Range: Minimum =20 points; Maximum=60 Higher score = better outcome

    Measured: 2 years

  4. Global development: Vineland Scale-III (VABS-III)

    Vineland Scale-III is designed to measure adaptive behavior of individuals from birth to age 90. The Vineland-II contains 5 domains each with 2-3 subdomains. The main domains are: Communication, Daily Living Skills, Socialization, Motor Skills, and Maladaptive Behavior.

    Measured: 2 years

  5. Global development: Aberrant behavior scale (ABC-C)

    Aberrant behavior scale (ABC-C). The ABC-C is a global behavior checklist that measures drug and other treatment effects in people with developmental disabilities. It is made up of five subscales, including Irritability, Lethargy, Inappropriate Speech, Hyperactivity, and Stereotypy based on 58 items that describe various behavioral problems.

    Measured: 2 years

  6. Communication assessment: ORCA communication tool (specifically designed for patients with AS)

    ORCA communication tool (specifically designed for patients with AS). Observed Reported Communication Assessment (ORCA) Tool. Questionnaire designed to be completed by the patients' main carer and records patient communication.

    Measured: 2 years

  7. Communication assessment: Leiter-3, Nonverbal Intelligence Scale

    -Leiter-3, Nonverbal Intelligence Scale (for patients with equivalent developmental age greater than 3 years 6 months). Is a totally nonverbal test of intelligence and cognitive abilities. Evaluates nonverbal cognitive, attentional, and neuropsychological abilities, and targets 'typical' as well as 'atypical' children, adolescents, and now adults.

    Measured: 2 years

  8. Sleep Disorders: Childhood Sleep Disorders Scale (Bruni Scale)

    -Childhood Sleep Disorders Scale (Bruni Scale). The SDSC is a 26-item scale developed to assess the presence of sleep difficulties in children within the previous six months.

    Divided items into six categories representing some of the most common sleep diffi culties affecting adolescents and children: disorders of initiating and maintaining sleep, sleep breathing disorders, disorders of arousal/nightmares, sleep-wake transition disorders, disorders of excessive somnolence, and sleep hyperhidrosis (nighttime sweating).

    The measure is completed by the parent of the child and takes approximately 5-10 min to complete. Item 1 measures the child's average hours of sleep, from 1 ('9 - 11 h') to 5 ('less than 5 h'). Item 2 measures the child's average time to fall asleep, from 1 ('less than 15 min') to 5 ('more than 60 min'). The remaining 24 items are rated on a 5-point Likert scale, from 1 ('Never') to 5 ('Always [daily]').

    Measured: 2 years

  9. Sleep Disorders: Children's Sleep Habits Questionnaire (CSHQ)

    -Children's Sleep Habits Questionnaire (CSHQ) This questionnaire was designed as a sleep screening instrument for school-aged children that yields final scores across eight subscales: bedtime resistance, sleep resistance, parasomnia, sleep disordered breathing, night-wakings, daytime sleepiness, sleep anxiety, and sleep onset delay, as well as a summative score, called the Total Sleep Disturbance score.

    Measured: 2 years

  10. Sleep Disorders: Diaries

    This study will utilize a brief 6-item sleep diary to collect parent-reported sleep variables (e.g., "what time was your child down for the night?").

    Measured: 2 years

  11. Proteomic analysis

    Proteomic analysis: Ubiquitin proteomics approach. Characterization of ubiquitination by Ube3a, a proteasomal component conserved from yeast (Ddi1) to humans (DDI1 and DDI2).

    Measured: 2 years

  12. Electroencephalogram (EEG) activity recordings

    Electroencephalogram (EEG) to record brain activity of Angelman Syndrome patients over a 4-hour period (e.g., sleep architecture, number and frequency of seizures, background epileptic activity, delta-rhythmicity)

    Measured: 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Nov 2023
  2. Study start1 Dec 2023
  3. Primary completion31 Dec 2024 (estimated)
  4. Study completion1 Jul 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
40 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06115109
Sponsor's protocol ID
01_FAST SPAIN
Status last verified
Apr 2024
First submitted
26 Jul 2022
Last updated
3 Apr 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Angelman Syndrome, run by Puerta de Hierro University Hospital at 2 sites in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 3 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact BELEN RUIZ ANTORAN, MD, Ph (+34911917479, bruizantoran@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Clinical Global Impression Scale for AS (CGI-AS) (time frame: 2 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Apr 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in